Details of the Drug

General Information of Drug (ID: DMIXC7G)

Drug Name
Zoledronate
Synonyms
Aclasta; Reclast; ZOL; Zometa; Novartis brand of zoledronic acid; Zoledronic acid; Zometa Concentrate; Bisphosphonate 3; CGP 42446; CGP 42446A; Aclasta (TN); CGP 42'446; CGP-42446; KS-1132; Reclast (TN); Zoledronic acid (INN); Zoledronic acid [USAN:INN]; Zomera (TN); Zometa (Novartis); Zometa (TN); CGP-42'446; Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid; [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid); (1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid; (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid; (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid; (1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate; 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid; 2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
Indication
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Approved [1]
Bone giant cell tumor N.A. Approved [2]
Bone Paget disease N.A. Approved [3]
Hypercalcaemia 5B91.0 Approved [4]
Multiple sclerosis 8A40 Approved [5]
Osteoporosis FB83.0 Approved [6]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Bone Density Conservation Agents
Affected Organisms
Humans and other mammals
ATC Code
M05BA08: Zoledronate
M05BA: Bisphosphonates
M05B: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
M05: DRUGS FOR TREATMENT OF BONE DISEASES
M: MUSCULO-SKELETAL SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 272.09
Logarithm of the Partition Coefficient (xlogp) -4.3
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 5
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 788 +/- 181 mcgh/L [7]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 370 +/- 78.5 mcg/L [7]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 0.317 +/- 0.014 h [7]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [8]
Clearance
The renal clearance of drug is 3.7 +/- 2.0 L/h [9]
Elimination
The drug is 39 +/- 16% eliminated in the urine as the unmetabolized parent drug [9]
Half-life
The concentration or amount of drug in body reduced by one-half in 146 hours [9]
Metabolism
The drug is not metabolised [9]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.0075 micromolar/kg/day [10]
Unbound Fraction
The unbound fraction of drug in plasma is 0.78% [11]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.6 L/kg [11]
Chemical Identifiers
Formula
C5H10N2O7P2
IUPAC Name
(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
Canonical SMILES
C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O
InChI
InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)
InChIKey
XRASPMIURGNCCH-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
68740
ChEBI ID
CHEBI:46557
CAS Number
118072-93-8
UNII
70HZ18PH24
DrugBank ID
DB00399
TTD ID
D0VM2L
VARIDT ID
DR01473
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Geranyltranstransferase (FDPS) TTIKWV4 FPPS_HUMAN Modulator [12]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [13]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon (AGPAT5) OTNY3VMD PLCE_HUMAN Gene/Protein Processing [14]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 (PLCB1) OT9HYT7A PLCB1_HUMAN Gene/Protein Processing [14]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-4 (PLCD4) OT14EZVB PLCD4_HUMAN Gene/Protein Processing [14]
11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1) OTO7FJA9 DHI1_HUMAN Gene/Protein Processing [14]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) OTHF4H9U DHI2_HUMAN Gene/Protein Processing [14]
14 kDa phosphohistidine phosphatase (PHPT1) OTFYWNFX PHP14_HUMAN Gene/Protein Processing [15]
14-3-3 protein zeta/delta OT2TKG9P 1433Z_HUMAN Gene/Protein Processing [16]
15-hydroxyprostaglandin dehydrogenase (HPGD) OTYZI6JB PGDH_HUMAN Gene/Protein Processing [14]
17-beta-hydroxysteroid dehydrogenase type 2 (HSD17B2) OT3K7HY5 DHB2_HUMAN Gene/Protein Processing [14]
182 kDa tankyrase-1-binding protein (TNKS1BP1) OTBIZECQ TB182_HUMAN Gene/Protein Processing [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 34 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC2 3.7661 5.7 0.3711 0.3733
ES7 GDSC2 0.1228 6.0877 -2.3074 22.6972
A-673 GDSC2 1.8635 3.6557 0.3041 2.4379
SK-ES-1 GDSC2 1.8922 4.0145 0.1556 3.2407
EW-1 GDSC2 1.9448 5.5595 -0.5484 7.3521
HuO-3N1 GDSC2 2.5123 6.0568 -0.4066 5.3364
NOS-1 [Human HNSCC] GDSC2 2.5611 5.5799 -0.1569 3.8356
EW-22 GDSC2 2.7116 4.8194 0.2577 1.4942
EW-3 GDSC2 2.7577 6.1037 -0.2785 4.1813
CAL-78 GDSC2 2.7749 4.6472 0.3579 1.0039
EW-18 GDSC2 2.7931 5.0988 0.1817 1.7525
EW-24 GDSC2 2.9072 4.405 0.507 0.4047
CHSA8926 GDSC2 2.9145 4.5936 0.4397 0.6019
EW-13 GDSC2 2.9229 5.2674 0.1758 1.6347
HuO9 GDSC2 3.0706 5.7066 0.0661 1.9719
EW-16 GDSC2 3.0808 5.6336 0.1016 1.7981
MG-63 GDSC2 3.101 5.04 0.3484 0.7833
CAL-72 GDSC2 3.1087 6.4773 -0.2451 3.4606
TC-71 GDSC2 3.1907 4.6852 0.5151 0.2672
EW-11 GDSC2 3.2638 6.9953 -0.3875 3.9758
MHH-ES-1 GDSC2 3.3042 5.0542 0.4262 0.431
CADO-ES1 GDSC2 3.3351 5.2197 0.3777 0.5479
HOS GDSC2 3.41 4.9401 0.5064 0.2161
SK-PN-DW GDSC2 3.4269 6.6393 -0.1462 2.5511
SaOS-2 GDSC2 3.4818 5.3657 0.3823 0.4633
EW-7 GDSC2 3.5193 5.343 0.405 0.3909
ES4 GDSC2 3.539 5.6407 0.3039 0.6524
NY GDSC2 3.5757 6.3989 0.0256 1.6287
ES8 GDSC2 3.6863 5.5822 0.3829 0.3766
U2OS GDSC2 3.7933 5.8286 0.3355 0.4449
ES6 GDSC2 3.8988 6.4311 0.1555 0.899
G-292 clone A141B1 GDSC2 3.9031 5.6589 0.4356 0.2092
ES5 GDSC2 4.03 7.2939 -0.1232 1.8201
H-EMC-SS GDSC2 4.3332 6.3605 0.3481 0.2465
⏷ Show the Full List of 34 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ESO-26 GDSC2 2.0546 4.1794 0.1795 2.811
KYSE-50 GDSC2 2.4671 5.5584 -0.2035 4.2585
KYAE-1 GDSC2 3.3534 5.1318 0.4172 0.4318
ESO-51 GDSC2 3.5151 5.3233 0.4104 0.3799
TE-12 GDSC2 3.905 6.8232 0.0069 1.4166
OACM5.1 C GDSC2 3.9371 6.2753 0.2292 0.6554
FLO-1 GDSC2 3.9652 6.3329 0.2192 0.669
SK-GT-4 GDSC2 4.0439 6.9219 0.0295 1.227
KYSE-220 GDSC2 4.3019 6.2938 0.3598 0.2352
OACP4 C GDSC2 4.5528 6.5724 0.3533 0.1913
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC2 3.336 5.3793 0.3185 0.7277
Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NB(TU)1 GDSC2 1.9454 3.8044 0.2854 2.403
SK-N-DZ GDSC2 2.4223 4.0431 0.4369 1.0051
Kelly GDSC2 2.5239 4.2882 0.3854 1.1256
CHP-212 GDSC2 2.5484 8.7918 -1.693 12.5498
CHP-134 GDSC2 2.5765 4.6761 0.2501 1.6846
SiMa GDSC2 2.6325 4.9282 0.1716 1.9953
IMR-5 GDSC2 2.6575 14.2448 -4.2968 23.4756
NH-12 GDSC2 2.7823 4.6699 0.3522 1.0199
SJNB-14 GDSC2 2.8695 5.0611 0.2349 1.4288
SJNB-10 GDSC2 3.0331 11.7637 -2.7959 16.8275
SK-N-AS GDSC2 3.1317 4.7925 0.4539 0.4391
SJNB-7 GDSC2 3.3066 5.1406 0.3955 0.5123
SK-N-BE(2)-M17 GDSC2 3.3238 5.1348 0.4045 0.479
GOTO GDSC2 3.4116 5.6082 0.2632 0.8609
TGW GDSC2 3.4592 5.0163 0.4978 0.2179
KP-N-YN GDSC2 3.4892 14.3923 -3.752 19.6852
SJNB-13 GDSC2 3.5823 5.0584 0.5272 0.1428
NB69 GDSC2 4.1862 17.2356 -4.64 21.2648
GI-ME-N GDSC2 4.3003 6.8214 0.1728 0.631
⏷ Show the Full List of 19 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuCC-T1 GDSC2 2.2428 8.5918 -1.8165 13.9352
Cancer Drug Sensitivity Data Curated from 42 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HCC2157 GDSC2 1.5607 5.1905 -0.6483 8.8872
MDA-MB-415 GDSC2 1.8233 4.4505 -0.0967 4.8821
CAL-120 GDSC2 1.9511 4.4233 0.0013 4.0332
HCC38 GDSC2 2.1791 4.6187 0.0533 3.3084
HCC1419 GDSC2 2.1924 4.2928 0.2091 2.4226
HCC1937 GDSC2 2.4907 4.5501 0.2594 1.7448
BT-20 GDSC2 2.7212 5.0921 0.1478 2
DU4475 GDSC2 2.7957 4.1478 0.5571 0.325
BT-474 GDSC2 2.8376 4.1896 0.5582 0.3041
HCC70 GDSC2 2.9009 5.2992 0.1517 1.7687
HCC1428 GDSC2 2.9209 4.52 0.47 0.5038
MFM-223 GDSC2 3.1072 4.5613 0.5277 0.2695
MRK-nu-1 GDSC2 3.1582 4.6617 0.5112 0.2871
MDA-MB-157 GDSC2 3.2048 5.446 0.2359 1.1155
AU565 GDSC2 3.2247 6.6644 -0.2635 3.3911
CAMA-1 GDSC2 3.2263 5.0164 0.4092 0.5153
BT-549 GDSC2 3.239 4.899 0.4571 0.3816
JIMT-1 GDSC2 3.2691 4.5565 0.5878 0.121
HDQ-P1 GDSC2 3.3142 7.3751 -0.528 4.6396
MDA-MB-453 GDSC2 3.3358 5.268 0.3601 0.5988
Evsa-T GDSC2 3.3562 4.7389 0.5564 0.1477
HCC1500 GDSC2 3.4052 5.286 0.3813 0.5022
ZR-75-30 GDSC2 3.4202 5.7536 0.2109 1.0387
Hs 578T GDSC2 3.5395 5.6678 0.294 0.6819
HCC1806 GDSC2 3.5467 5.4607 0.3731 0.4576
MDA-MB-231 GDSC2 3.5485 5.408 0.3928 0.408
EFM-192A GDSC2 3.5775 5.1895 0.4806 0.2161
MDA-MB-436 GDSC2 3.6231 5.3152 0.4535 0.2522
MDA-MB-361 GDSC2 3.6332 5.2356 0.4847 0.1952
CAL-51 GDSC2 3.6681 5.53 0.3946 0.3573
HCC1187 GDSC2 3.6847 5.5624 0.3894 0.3629
MDA-MB-468 GDSC2 3.727 5.4757 0.4355 0.2554
MCF-7 GDSC2 3.7622 6.0913 0.2268 0.7579
HCC1954 GDSC2 3.7907 5.4918 0.4529 0.2085
OCUB-M GDSC2 3.8206 5.2998 0.5283 0.1016
T-47D GDSC2 3.8647 5.9831 0.3073 0.4834
CAL-85-1 GDSC2 3.8783 6.0019 0.3058 0.4814
MDA-MB-330 GDSC2 4.0107 6.5146 0.1702 0.7866
COLO 824 GDSC2 4.0691 6.0316 0.3666 0.284
EFM-19 GDSC2 4.1049 5.9639 0.4029 0.2136
HCC1569 GDSC2 4.2573 6.4918 0.2747 0.4065
HCC1143 GDSC2 4.6831 6.936 0.2753 0.2795
⏷ Show the Full List of 42 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 34 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PFSK-1 GDSC2 1.7344 5.6113 -0.7259 8.928
AM-38 GDSC2 1.7803 4.0082 0.0859 3.8729
H4 GDSC2 1.9695 7.0758 -1.2726 11.594
Daoy GDSC2 2.0796 3.9478 0.2989 2.1126
KS-1 [Human Krukenberg tumour] GDSC2 2.2951 4.6687 0.0995 2.8567
42-MG-BA GDSC2 2.4061 4.3825 0.2869 1.7166
SF539 GDSC2 2.5135 4.5674 0.2638 1.6952
U-87MG ATCC GDSC2 2.5936 4.5343 0.3179 1.3504
LN-18 GDSC2 2.6019 3.7445 0.6278 0.2343
Becker GDSC2 2.6508 6.0776 -0.3306 4.6529
GB-1 GDSC2 2.9156 4.6584 0.4156 0.6812
A-172 GDSC2 2.9722 4.9518 0.3264 0.96
U-251MG GDSC2 3.0023 4.6745 0.4456 0.531
LN-229 GDSC2 3.0162 5.0293 0.3155 0.9657
8-MG-BA GDSC2 3.1272 6.6341 -0.304 3.7411
DBTRG-05MG GDSC2 3.136 5.054 0.3579 0.7272
ONS-76 GDSC2 3.1741 4.7757 0.4765 0.3615
CAS-1 GDSC2 3.1772 4.7821 0.4754 0.3628
DK-MG GDSC2 3.2267 4.493 0.5945 0.1201
GI-1 GDSC2 3.2639 5.2773 0.3269 0.7463
YH-13 GDSC2 3.2786 4.8166 0.5014 0.2659
M059J GDSC2 3.291 5.1451 0.3876 0.5429
T98G GDSC2 3.297 5.0454 0.4266 0.4333
D283 Med GDSC2 3.363 4.9999 0.4682 0.307
D-263MG GDSC2 3.3951 5.1941 0.4108 0.4294
KINGS-1 GDSC2 3.4356 6.4735 -0.0723 2.1977
GaMG GDSC2 3.4926 4.894 0.5515 0.1272
U-118MG GDSC2 3.5208 5.0295 0.5154 0.1732
LN-405 GDSC2 3.5413 5.4194 0.3859 0.4279
SW1088 GDSC2 3.6037 5.7829 0.2773 0.6959
SF268 GDSC2 3.6605 5.6691 0.3418 0.4864
KALS-1 GDSC2 3.6767 6.0533 0.2057 0.8773
SK-MG-1 GDSC2 3.9361 5.4663 0.5122 0.1024
D-392MG GDSC2 3.988 6.0558 0.3282 0.3867
⏷ Show the Full List of 34 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ETK-1 GDSC2 3.2852 5.7289 0.16 1.3455
TGBC24TKB GDSC2 3.3901 5.3408 0.3551 0.5839
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MFE-319 GDSC2 2.0331 5.7122 -0.5606 7.2271
ESS-1 GDSC2 2.3571 4.2818 0.3044 1.6931
RL95-2 GDSC2 2.802 5.0121 0.2223 1.5563
EN GDSC2 3.0444 4.3151 0.5908 0.1668
MFE-296 GDSC2 3.7153 6.0404 0.2266 0.7861
KLE GDSC2 3.746 5.8409 0.3128 0.5224
AN3-CA GDSC2 3.763 6.0622 0.238 0.7234
MFE-280 GDSC2 4.143 6.6081 0.1888 0.6635
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 128 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LC4-1 GDSC2 -0.9921 3.0178 -1.9295 25.061
HH [Human lymphoma] GDSC2 -0.4274 2.1528 -0.9742 17.3763
CTV-1 GDSC2 0.6154 3.7598 -0.7122 11.9953
L-363 GDSC2 1.5488 10.6028 -3.3521 22.8961
P32/ISH GDSC2 1.5814 3.8229 0.0388 4.5885
MHH-CALL-2 GDSC2 1.6318 3.1985 0.3722 2.4698
SCC-3 GDSC2 1.8036 3.8125 0.1938 3.1863
AMO1 GDSC2 1.8216 6.6814 -1.1884 11.4744
JURL-MK1 GDSC2 1.8911 3.8077 0.251 2.6916
MOLM-13 GDSC2 1.899 4.2621 0.0436 3.8859
RPMI-8866 GDSC2 1.9029 6.0194 -0.8027 8.9848
SUP-M2 GDSC2 1.9544 3.7691 0.3068 2.2687
OCI-AML-5 GDSC2 2.0214 3.2246 0.5796 0.7914
OCI-M1 GDSC2 2.0669 3.5756 0.455 1.3219
Granta-519 GDSC2 2.1471 3.9913 0.3175 1.9131
DEL GDSC2 2.1594 3.4149 0.5676 0.7082
MOLT-13 GDSC2 2.1739 4.5386 0.0869 3.128
HEL GDSC2 2.196 3.7495 0.4476 1.1997
SU-DHL-10 GDSC2 2.1977 3.1874 0.6723 0.3059
Jurkat GDSC2 2.2035 3.4943 0.5561 0.7148
ME1 GDSC2 2.2297 3.5274 0.5549 0.6964
BL-41 GDSC2 2.2999 3.4383 0.6202 0.4067
DoHH2 GDSC2 2.3115 4.0942 0.3608 1.4749
Namalwa GDSC2 2.3236 4.1331 0.3505 1.5097
TK [Human B-cell lymphoma] GDSC2 2.3725 4.0159 0.4241 1.1114
CML-T1 GDSC2 2.381 4.5248 0.2119 2.1286
NCI-H929 GDSC2 2.464 5.1131 -0.0026 3.1448
Jiyoye GDSC2 2.5194 12.7253 -3.6495 21.5302
KE-37 GDSC2 2.5361 3.9958 0.5074 0.6295
Farage GDSC2 2.5392 4.262 0.4033 1.0341
Hs 445 GDSC2 2.5442 4.3094 0.3864 1.1006
HC-1 GDSC2 2.5548 4.282 0.4025 1.0223
NOMO-1 GDSC2 2.5582 4.0485 0.4966 0.6519
TUR GDSC2 2.5671 4.3342 0.3872 1.075
Karpas-231 GDSC2 2.5756 3.827 0.5876 0.3485
ST486 GDSC2 2.5951 4.2734 0.4246 0.8953
GDM-1 GDSC2 2.5964 5.4963 -0.0983 3.4559
KOPN-8 GDSC2 2.5992 4.5765 0.3032 1.411
MOLP-8 GDSC2 2.6338 4.68 0.2772 1.4913
RS4;11 GDSC2 2.6394 4.459 0.3707 1.0752
ALL-SIL GDSC2 2.6554 4.2272 0.4696 0.6767
SKM-1 GDSC2 2.656 4.0612 0.5332 0.4644
ARH-77 GDSC2 2.669 4.2654 0.4608 0.6985
Karpas-422 GDSC2 2.6751 5.135 0.1051 2.2702
HL-60 GDSC2 2.6856 3.9879 0.5722 0.3364
IM-9 GDSC2 2.7208 4.0146 0.5762 0.3097
Karpas-299 GDSC2 2.7454 4.3868 0.4469 0.6917
SU-DHL-8 GDSC2 2.7478 4.2761 0.4903 0.5438
SU-DHL-5 GDSC2 2.7556 3.8868 0.6347 0.1679
EoL-1 GDSC2 2.7711 4.6617 0.3503 1.0374
Raji GDSC2 2.779 4.1543 0.5482 0.3559
GA-10 GDSC2 2.7957 4.4005 0.4631 0.6018
Karpas-620 GDSC2 2.8024 4.1944 0.5427 0.3592
LP-1 GDSC2 2.8039 4.5672 0.4024 0.8086
OCI-AML-2 GDSC2 2.8061 4.0262 0.6045 0.2114
A3/Kawakami GDSC2 2.8097 3.9558 0.6304 0.1605
U266B1 GDSC2 2.8213 8.2769 -1.2554 9.5566
JVM-3 GDSC2 2.8534 4.5156 0.4437 0.6283
RPMI-8226 GDSC2 2.8636 5.2621 0.1486 1.8257
ML-2 GDSC2 2.868 4.4711 0.4666 0.5452
OPM-2 GDSC2 2.8715 4.7811 0.3486 0.9579
P12-Ichikawa GDSC2 2.905 4.3583 0.5232 0.3625
EM-2 GDSC2 2.9185 4.5141 0.4712 0.5014
KMS-12-BM GDSC2 2.9225 4.6767 0.4115 0.6902
Daudi GDSC2 2.9305 4.3776 0.5261 0.3435
Loucy GDSC2 2.936 4.5413 0.4682 0.5005
P30/OHK GDSC2 2.9497 5.2354 0.202 1.4903
WSU-NHL GDSC2 2.9519 4.6786 0.4232 0.6319
PF-382 GDSC2 2.9781 4.8288 0.3769 0.7711
Ramos.2G6.4C10 GDSC2 2.9893 4.4493 0.523 0.326
NALM-6 GDSC2 2.9962 4.9879 0.3229 0.9539
CCRF-CEM GDSC2 3.0062 4.5845 0.4804 0.4285
SR GDSC2 3.0161 4.5255 0.5058 0.357
K-562 GDSC2 3.0261 4.6375 0.4689 0.4505
Reh GDSC2 3.033 4.561 0.4995 0.3654
RC-K8 GDSC2 3.046 4.3705 0.5721 0.1997
697 GDSC2 3.0474 4.7135 0.4494 0.4949
MM1.S GDSC2 3.0523 12.7654 -3.2723 18.8016
OCI-AML-3 GDSC2 3.0562 4.8188 0.4137 0.5974
JJN-3 GDSC2 3.0612 4.4536 0.5486 0.2413
EJM GDSC2 3.0689 4.9168 0.3819 0.6919
KG-1 GDSC2 3.1354 4.8629 0.4294 0.5053
U-698-M GDSC2 3.1388 5.0032 0.3784 0.6586
SK-MM-2 GDSC2 3.1614 5.7517 0.0922 1.7542
SUP-B15 GDSC2 3.181 5.1101 0.3556 0.7058
MOLT-16 GDSC2 3.2012 4.917 0.4358 0.4542
JSC-1 GDSC2 3.2159 8.7661 -1.2282 8.6129
Ku812 GDSC2 3.2429 5.1854 0.3529 0.6754
MHH-PREB-1 GDSC2 3.2436 4.9341 0.4462 0.4071
KCL-22 GDSC2 3.268 5.3076 0.3171 0.7761
KY821 GDSC2 3.2917 4.9416 0.462 0.3479
KM-H2 GDSC2 3.2927 5.2752 0.3398 0.6866
A4/Fukuda GDSC2 3.3227 4.8988 0.4889 0.277
SU-DHL-6 GDSC2 3.3273 4.9798 0.4619 0.3343
EB2 GDSC2 3.3317 5.0405 0.4418 0.3798
CESS GDSC2 3.3388 5.2615 0.3638 0.5864
RPMI-6666 GDSC2 3.3739 5.2236 0.3918 0.4891
ATN-1 GDSC2 3.3855 4.9005 0.5113 0.2142
LAMA-84 GDSC2 3.4211 6.1998 0.0335 1.7445
WIL2 NS GDSC2 3.429 5.1446 0.4416 0.3417
HDLM-2 GDSC2 3.4384 5.4888 0.3196 0.6624
JVM-2 GDSC2 3.4622 6.0827 0.0999 1.4294
ALL-PO GDSC2 3.5098 5.922 0.1846 1.0666
L-1236 GDSC2 3.5173 5.7231 0.264 0.7891
BE-13 GDSC2 3.5218 5.353 0.4023 0.3962
DND-41 GDSC2 3.5298 5.0438 0.5137 0.1737
DG-75 GDSC2 3.5372 5.6052 0.3164 0.6168
L-428 GDSC2 3.5452 5.1488 0.483 0.2206
DB GDSC2 3.5482 5.075 0.5095 0.1759
SUP-T1 GDSC2 3.5565 5.469 0.3739 0.4512
GR-ST GDSC2 3.557 6.5314 -0.037 1.912
KMOE-2 GDSC2 3.5784 5.64 0.3201 0.5845
Kasumi-1 GDSC2 3.5929 5.4219 0.4048 0.3627
BALL-1 GDSC2 3.6232 5.3689 0.4348 0.2884
VL51 GDSC2 3.6264 5.421 0.4176 0.3226
MLMA GDSC2 3.6351 5.5221 0.385 0.3917
MOLT-4 GDSC2 3.6945 5.2799 0.4913 0.171
Karpas-45 GDSC2 3.716 5.216 0.5204 0.127
Karpas-1106P GDSC2 3.7545 5.4386 0.4583 0.2086
L-540 GDSC2 3.8722 5.279 0.5526 0.072
SUP-HD1 GDSC2 3.8926 5.9439 0.3321 0.4135
BC-1 GDSC2 3.8928 19.0915 -5.7627 25.0523
CA46 GDSC2 4.0152 5.904 0.3914 0.2548
H9 GDSC2 4.0486 5.5662 0.5171 0.0834
MEG-01 GDSC2 4.0532 6.3274 0.2558 0.5299
VAL GDSC2 4.1342 6.028 0.3913 0.225
HAL-01 GDSC2 4.2027 6.1175 0.385 0.2189
MN-60 GDSC2 4.4697 6.2217 0.4422 0.1025
⏷ Show the Full List of 128 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
786-O GDSC2 1.7904 3.7095 0.2337 2.9778
SW13 GDSC2 2.275 4.3044 0.2504 2.0791
KTCTL-195 GDSC2 2.3131 4.4032 0.2279 2.1415
A-498 GDSC2 2.575 4.3785 0.3729 1.128
SN12C GDSC2 2.6951 4.6847 0.3053 1.3
BFTC-909 GDSC2 2.88 4.4113 0.4938 0.456
OS-RC-2 GDSC2 2.9677 4.6264 0.4494 0.5393
LB996-RCC GDSC2 2.9681 5.8509 -0.0482 2.6502
CAL-54 GDSC2 3.0249 8.245 -1.1059 8.315
A-704 GDSC2 3.1183 4.7258 0.4729 0.395
VMRC-RCZ GDSC2 3.1477 4.8313 0.446 0.4526
RCC10RGB GDSC2 3.1632 4.5735 0.5442 0.2177
KMRC-20 GDSC2 3.3264 4.9243 0.4812 0.2919
ACHN GDSC2 3.6045 5.3627 0.4301 0.304
HA7-RCC GDSC2 3.6186 5.5884 0.3548 0.4722
769-P GDSC2 3.6583 5.5233 0.3934 0.3638
TK-10 GDSC2 4.1565 6.8484 0.1051 0.9009
RXF 393L GDSC2 4.1804 6.4769 0.2509 0.4887
NCC010 GDSC2 4.2388 6.2952 0.3367 0.2905
⏷ Show the Full List of 19 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 46 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO205 GDSC2 2.0669 3.8959 0.3148 2.0463
SW948 GDSC2 2.2868 4.2837 0.266 1.9816
SW1116 GDSC2 2.5362 4.5274 0.2923 1.5328
LoVo GDSC2 2.5375 5.0215 0.0799 2.5916
HT-29 GDSC2 2.5612 3.7422 0.6129 0.2876
HCT 116 GDSC2 2.566 3.8235 0.5851 0.3607
CCK-81 GDSC2 2.5803 4.7458 0.2224 1.8131
MDST8 GDSC2 2.679 4.1624 0.5045 0.5413
C2BBe1 GDSC2 2.8226 10.2259 -2.1964 14.5064
HT115 GDSC2 2.832 4.5538 0.4199 0.7247
SW1417 GDSC2 2.8463 4.809 0.326 1.0685
KM12 GDSC2 2.8692 5.0083 0.2564 1.3363
LS411N GDSC2 2.8806 4.2103 0.5671 0.2656
SNU-61 GDSC2 2.9282 4.9821 0.2945 1.1223
CL-11 GDSC2 2.9284 5.1805 0.2143 1.4586
LS1034 GDSC2 2.9841 4.2702 0.5845 0.1949
SNU-175 GDSC2 3.0003 4.8321 0.3851 0.7269
LS513 GDSC2 3.0229 4.6208 0.4737 0.4386
RCM-1 [Human ESC] GDSC2 3.1038 4.6308 0.5017 0.33
RKO GDSC2 3.1533 4.9044 0.4213 0.5193
HT-55 GDSC2 3.1569 4.6789 0.5047 0.3021
COLO 320HSR GDSC2 3.1905 4.7436 0.4943 0.3129
SNU-1040 GDSC2 3.2361 4.509 0.5924 0.1212
LS123 GDSC2 3.2705 5.3698 0.2944 0.8515
HCT 15 GDSC2 3.2759 4.8417 0.4916 0.2875
SNU-C1 GDSC2 3.3014 5.4264 0.2859 0.8594
SW48 GDSC2 3.3231 6.6005 -0.1833 2.8575
SW1463 GDSC2 3.3736 5.2929 0.3661 0.5608
SNU-81 GDSC2 3.4338 5.186 0.4286 0.3695
NCI-H716 GDSC2 3.4366 5.4248 0.3427 0.5948
T84 GDSC2 3.4447 5.2576 0.407 0.4172
GP5d GDSC2 3.4476 5.1554 0.4448 0.3276
SNU-C5 GDSC2 3.5461 5.515 0.3531 0.5099
SW837 GDSC2 3.549 5.5407 0.3449 0.5306
HCC2998 GDSC2 3.5575 5.8696 0.2253 0.8905
DiFi GDSC2 3.5675 5.7082 0.2903 0.6771
SK-CO-1 GDSC2 3.5981 5.161 0.4978 0.1827
CW-2 GDSC2 3.6005 5.5683 0.355 0.4796
CaR-1 GDSC2 3.6407 5.5937 0.3614 0.4459
LS180 GDSC2 3.7334 5.1433 0.5507 0.0903
NCI-H747 GDSC2 3.8141 5.8771 0.326 0.459
SW626 GDSC2 3.8242 5.7194 0.386 0.3214
SNU-407 GDSC2 3.8591 5.7725 0.3802 0.3218
SW620 GDSC2 3.8897 5.5263 0.4761 0.1528
COLO 678 GDSC2 4.1139 5.7728 0.4706 0.1216
SNU-C2B GDSC2 4.3944 7.0895 0.1118 0.7498
⏷ Show the Full List of 46 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC2 3.0909 4.5574 0.523 0.2859
Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-423 GDSC2 2.1581 5.1064 -0.1869 4.7358
SK-HEP-1 GDSC2 2.4765 3.8523 0.5371 0.5679
JHH-6 GDSC2 2.5203 3.6068 0.646 0.2242
Hep 3B2.1-7 GDSC2 2.6216 4.2836 0.4326 0.8414
JHH-1 GDSC2 2.6423 3.9817 0.5572 0.4002
Hep-G2/C3A GDSC2 2.9177 4.5087 0.4729 0.4968
JHH-2 GDSC2 2.9717 6.0548 -0.135 3.0866
HLE GDSC2 3.0744 5.3444 0.2168 1.3062
HuH-1 GDSC2 3.1327 4.7161 0.4821 0.3655
SNU-387 GDSC2 3.1604 4.7933 0.4649 0.3967
JHH-7 GDSC2 3.3655 5.4804 0.2925 0.7937
JHH-4 GDSC2 3.4361 5.0547 0.476 0.266
SNU-398 GDSC2 3.692 5.5973 0.3797 0.3818
SNU-449 GDSC2 3.8235 5.6012 0.4269 0.244
Huh-7 GDSC2 3.9271 5.3577 0.5451 0.0725
⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 129 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H1155 GDSC2 1.3285 5.3538 -0.9095 11.1017
COR-L311 GDSC2 2.0165 5.2436 -0.3461 5.9727
NCI-H2795 GDSC2 2.0284 19.3481 -7.3317 32.3183
NCI-H345 GDSC2 2.1225 2.9971 0.7124 0.2312
NCI-H226 GDSC2 2.1592 3.6287 0.4798 1.092
LOU-NH91 GDSC2 2.1684 4.56 0.0738 3.2111
Lu-165 GDSC2 2.235 3.9327 0.39 1.428
EBC-1 GDSC2 2.2668 5.0845 -0.1078 4.0715
Lu-139 GDSC2 2.2999 4.646 0.1125 2.7778
SBC-5 GDSC2 2.309 3.3222 0.6671 0.263
NCI-H1563 GDSC2 2.3427 4.2986 0.2896 1.7853
NCI-H661 GDSC2 2.3553 4.7449 0.1 2.7587
HOP-92 GDSC2 2.3661 9.1632 -2.0066 14.6272
KNS-62 GDSC2 2.3927 4.4403 0.255 1.8929
DMS 79 GDSC2 2.4005 4.941 0.0381 3.0238
NCI-H322M GDSC2 2.4162 5.3645 -0.1453 4.0186
NCI-H2029 GDSC2 2.4762 4.1047 0.4373 0.9515
NCI-H2141 GDSC2 2.4991 4.0381 0.4745 0.7816
NCI-H1048 GDSC2 2.5379 6.7195 -0.702 6.9941
HCC78 GDSC2 2.5669 8.1465 -1.3666 10.7249
NCI-H1876 GDSC2 2.5908 4.6085 0.2857 1.5006
NCI-H720 GDSC2 2.6017 3.7927 0.6104 0.2761
NCI-H2122 GDSC2 2.7371 4.2201 0.5069 0.4977
Calu-3 GDSC2 2.7518 5.2101 0.1133 2.1301
SHP-77 GDSC2 2.7923 4.4136 0.4567 0.6255
DMS 53 GDSC2 2.8142 4.9645 0.2479 1.429
NCI-H1581 GDSC2 2.8371 4.4196 0.4732 0.543
NCI-H1781 GDSC2 2.8414 4.7994 0.3276 1.0663
EPLC-272H GDSC2 2.8758 4.9795 0.2711 1.2672
NCI-H2369 GDSC2 2.8833 4.2212 0.5643 0.2711
LCLC-103H GDSC2 2.8836 4.0715 0.617 0.1639
NCI-H526 GDSC2 2.8882 4.1704 0.5842 0.2258
COR-L23 GDSC2 2.8945 4.3421 0.525 0.3626
NCI-H1963 GDSC2 2.8976 5.4732 0.0768 2.1258
NCI-H1793 GDSC2 2.9164 4.8494 0.3418 0.947
NCI-H446 GDSC2 2.9253 5.0814 0.2532 1.2952
RERF-LC-Sq1 GDSC2 2.9284 7.2686 -0.71 6.2891
NCI-H196 GDSC2 2.9429 4.3926 0.5255 0.3396
NCI-H596 GDSC2 2.9581 4.6085 0.4521 0.5365
NCI-H82 GDSC2 3.0334 4.3935 0.5595 0.2283
NCI-H727 GDSC2 3.0513 5.0722 0.3143 0.9423
IA-LM GDSC2 3.0569 4.6022 0.4939 0.3691
NCI-H2373 GDSC2 3.078 4.9253 0.3825 0.684
VMRC-LCD GDSC2 3.0827 4.9323 0.3818 0.6832
NCI-H2135 GDSC2 3.1147 4.6793 0.4884 0.3577
HOP-62 GDSC2 3.1161 5.3872 0.2189 1.2594
NCI-H810 GDSC2 3.1175 4.6442 0.5021 0.3234
NCI-H1568 GDSC2 3.1284 6.6691 -0.3188 3.8168
HCC15 GDSC2 3.1524 5.4091 0.2268 1.1955
CPC-N GDSC2 3.1544 5.4116 0.2267 1.1941
UMC-11 GDSC2 3.1599 4.8292 0.4516 0.4316
NCI-H23 GDSC2 3.1995 5.0563 0.3835 0.606
NCI-H1755 GDSC2 3.2064 5.2506 0.3127 0.8331
NCI-H1623 GDSC2 3.2175 5.2601 0.3138 0.8215
NCI-H1092 GDSC2 3.2246 5.1417 0.3618 0.6586
Ms-1 GDSC2 3.2271 4.6785 0.5309 0.2238
SBC-3 GDSC2 3.2449 5.0793 0.3934 0.5509
NCI-H1355 GDSC2 3.257 5.5909 0.2021 1.2028
NCI-H1435 GDSC2 3.2606 4.9124 0.4606 0.364
NCI-H3122 GDSC2 3.261 5.3301 0.3056 0.8197
NCI-H2023 GDSC2 3.2652 4.9293 0.4562 0.3727
SW1573 GDSC2 3.2718 6.3296 -0.0944 2.4912
NCI-H3255 GDSC2 3.3015 5.3371 0.32 0.7445
PC-14 GDSC2 3.3218 4.9624 0.466 0.3272
NCI-H2818 GDSC2 3.3234 5.0791 0.4246 0.4263
EKVX GDSC2 3.3243 6.1974 -0.0125 2.0486
NCI-H2085 GDSC2 3.3352 5.1211 0.414 0.4485
NCI-H524 GDSC2 3.3454 5.0114 0.4574 0.3375
NCI-H1299 GDSC2 3.4089 5.4414 0.3252 0.6623
NCI-H2810 GDSC2 3.4181 5.9679 0.1256 1.3657
DMS 273 GDSC2 3.4315 5.8626 0.1733 1.1692
LK-2 GDSC2 3.4328 5.3018 0.3864 0.4754
Lu-135 GDSC2 3.4404 5.527 0.3061 0.7029
LCLC-97TM1 GDSC2 3.446 5.7325 0.2302 0.9507
SK-MES-1 GDSC2 3.4461 5.5032 0.3173 0.6649
NCI-H2227 GDSC2 3.4485 5.2227 0.4211 0.3814
HCC44 GDSC2 3.4845 5.5472 0.3166 0.6452
HARA [Human squamous cell lung carcinoma] GDSC2 3.4922 5.3752 0.3829 0.457
RERF-LC-KJ GDSC2 3.4925 5.3823 0.3804 0.4633
Lu-99A GDSC2 3.5004 5.4977 0.3413 0.5649
NCI-H1915 GDSC2 3.5179 5.2365 0.4423 0.3078
NCI-H211 GDSC2 3.5243 5.2915 0.4252 0.3425
NCI-H250 GDSC2 3.5251 5.6847 0.2818 0.728
NCI-H1694 GDSC2 3.5264 5.2645 0.4357 0.319
NCI-H1975 GDSC2 3.555 5.4654 0.3746 0.4502
NCI-H650 GDSC2 3.573 7.5575 -0.4641 3.9256
NCI-H513 GDSC2 3.5814 5.4205 0.4009 0.3759
HCC827 GDSC2 3.5898 5.4404 0.397 0.3817
NCI-H2722 GDSC2 3.5935 5.4745 0.3861 0.4056
COLO 668 GDSC2 3.6049 5.2515 0.4691 0.2291
ABC-1 GDSC2 3.6182 5.7009 0.3135 0.5826
NCI-H2595 GDSC2 3.6326 5.7951 0.2845 0.6581
Lu-65 GDSC2 3.6539 5.7725 0.3014 0.5981
HCC366 GDSC2 3.6835 5.7234 0.331 0.5037
NCI-H841 GDSC2 3.6906 5.1563 0.5317 0.1175
NCI-H2228 GDSC2 3.6923 5.9578 0.2481 0.7333
NCI-H1869 GDSC2 3.6928 5.3652 0.4614 0.2189
SW1271 GDSC2 3.6999 5.4802 0.4241 0.2853
NCI-H1650 GDSC2 3.7115 5.7243 0.3416 0.4644
NCI-H2170 GDSC2 3.7451 5.9993 0.2542 0.6854
SK-LU-1 GDSC2 3.7458 5.5635 0.4117 0.2952
NCI-H1666 GDSC2 3.7466 6.137 0.2032 0.8409
NCI-H1693 GDSC2 3.7713 5.8685 0.3126 0.5113
NCI-H1993 GDSC2 3.8014 5.67 0.3949 0.3109
NCI-H522 GDSC2 3.8071 5.5229 0.4481 0.2123
NCI-H1651 GDSC2 3.8076 5.7123 0.3823 0.3346
NCI-H2803 GDSC2 3.8132 5.395 0.4938 0.1437
EMC-BAC-2 GDSC2 3.8412 6.5763 0.0752 1.2132
NCI-H2087 GDSC2 3.8439 6.2264 0.2097 0.7626
NCI-H520 GDSC2 3.8491 5.7197 0.395 0.2956
DMS 114 GDSC2 3.8597 5.6099 0.4369 0.2176
A-549 GDSC2 3.8817 6.1602 0.2495 0.627
IST-SL2 GDSC2 3.9196 5.9331 0.3461 0.3724
NCI-H209 GDSC2 3.9337 6.0092 0.3243 0.4153
NCI-H2405 GDSC2 3.9399 6.1529 0.275 0.5315
NCI-H2591 GDSC2 3.9426 6.0932 0.2976 0.4743
NCI-H1792 GDSC2 3.9904 5.7791 0.4255 0.2048
Calu-6 GDSC2 4.0167 5.7138 0.4569 0.1545
NCI-H358 GDSC2 4.0194 6.0642 0.337 0.3571
NCI-H2731 GDSC2 4.0352 6.285 0.2642 0.517
NCI-H1944 GDSC2 4.0628 6.4907 0.2001 0.6726
NCI-H2804 GDSC2 4.1044 6.5861 0.1815 0.7032
NCI-H441 GDSC2 4.2172 6.4583 0.2715 0.4277
LXF 289 GDSC2 4.2726 14.7956 -3.3977 16.7066
A-427 GDSC2 4.287 6.8734 0.1486 0.7024
COR-L105 GDSC2 4.3764 7.206 0.0614 0.9062
NCI-H2869 GDSC2 4.4149 6.5148 0.3243 0.2654
LC-1/sq GDSC2 4.4356 6.5003 0.3366 0.2405
NCI-H2461 GDSC2 4.5661 6.3666 0.4267 0.1053
⏷ Show the Full List of 129 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC2 3.2037 5.0298 0.3951 0.5686
Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE-6 GDSC2 2.0085 6.8348 -1.1256 10.6457
OE33 GDSC2 2.9059 4.8717 0.3282 1.008
KYSE-450 GDSC2 2.9439 4.2118 0.5902 0.1961
TE-1 GDSC2 3.0029 10.3346 -2.1218 13.7318
OE21 GDSC2 3.0396 4.8524 0.394 0.671
KYSE-510 GDSC2 3.0499 5.0447 0.3244 0.9062
TE-5 GDSC2 3.105 4.7124 0.4726 0.4019
TE-9 GDSC2 3.1171 4.4454 0.5719 0.1801
TE-8 GDSC2 3.162 5.3153 0.2682 1.0274
KYSE-70 GDSC2 3.1704 5.324 0.2685 1.0196
OE19 GDSC2 3.3398 4.5936 0.5998 0.0941
KYSE-180 GDSC2 3.3763 5.4285 0.3166 0.7086
KYSE-140 GDSC2 3.5187 5.4335 0.3721 0.4729
KYSE-270 GDSC2 3.5824 6.1966 0.1093 1.2899
EC-GI-10 GDSC2 3.6369 5.2768 0.4719 0.2156
TE-4 GDSC2 3.7276 5.6134 0.3874 0.3516
TE-15 GDSC2 3.7399 6.011 0.2477 0.7076
COLO 680N GDSC2 3.779 5.5581 0.4258 0.2585
KYSE-520 GDSC2 4.0756 6.2968 0.2754 0.4729
KYSE-410 GDSC2 4.0975 6.4615 0.2244 0.5902
⏷ Show the Full List of 20 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TYK-nu GDSC2 1.1303 3.8755 -0.3307 8.0501
OVISE GDSC2 1.898 3.574 0.362 2.0557
OVCAR-8 GDSC2 2.1267 4.3584 0.1409 2.9051
A2780 GDSC2 2.2126 5.3971 -0.2887 5.2276
OAW42 GDSC2 2.3137 3.5291 0.5915 0.4937
OV56 GDSC2 2.5611 3.7151 0.6227 0.2631
TOV-112D GDSC2 2.6613 4.7635 0.256 1.558
DOV13 GDSC2 2.7724 4.6016 0.3749 0.9389
TOV-21G GDSC2 2.9474 4.6894 0.4171 0.6547
OVCAR-3 GDSC2 3.1051 4.7349 0.4644 0.4235
OV-90 GDSC2 3.2732 4.8795 0.4771 0.3202
OVCAR-5 GDSC2 3.3099 4.9379 0.4702 0.3221
OVTOKO GDSC2 3.37 5.7584 0.1868 1.1677
OVK18 GDSC2 3.3712 5.0089 0.4681 0.3043
EFO-21 GDSC2 3.4359 5.0104 0.4914 0.2363
ES-2 GDSC2 3.4847 4.9495 0.5299 0.1591
IGROV-1 GDSC2 3.5771 5.8444 0.2431 0.819
OVCAR-4 GDSC2 3.6165 5.5105 0.382 0.406
OAW28 GDSC2 3.6382 5.744 0.3056 0.5943
Kuramochi GDSC2 4.0018 5.8462 0.4065 0.2326
SK-OV-3 GDSC2 4.0079 5.6707 0.4684 0.1413
EFO-27 GDSC2 4.5123 15.1825 -3.4208 16.3286
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KP-2 GDSC2 1.9399 3.7671 0.2991 2.3355
HPAC GDSC2 2.0509 12.2424 -3.7712 23.1484
SUIT-2 GDSC2 2.2367 4.191 0.2791 1.9843
YAPC GDSC2 2.486 4.3391 0.346 1.341
MIA PaCa-2 GDSC2 2.4873 4.2326 0.3906 1.1401
PSN1 GDSC2 2.491 10.3911 -2.5183 16.8375
PaTu 8902 GDSC2 2.5809 3.9996 0.5251 0.5372
SU.86.86 GDSC2 2.5833 4.1527 0.467 0.7415
DAN-G GDSC2 2.611 7.8841 -1.2095 9.7486
PaTu 8988t GDSC2 2.644 4.0077 0.5482 0.4257
QGP-1 GDSC2 2.6468 4.4632 0.3724 1.061
Panc 02.03 GDSC2 2.843 10.7383 -2.4317 15.5961
KP-4 GDSC2 2.8945 4.3083 0.5373 0.3312
HuP-T3 GDSC2 3.0925 4.96 0.3754 0.6978
PL4 GDSC2 3.2208 5.3904 0.2648 0.9937
Capan-1 GDSC2 3.3657 4.9839 0.4749 0.2917
Capan-2 GDSC2 3.405 5.7402 0.2094 1.0557
CFPAC-1 GDSC2 3.5225 5.0558 0.507 0.1861
Panc 08.13 GDSC2 3.589 5.5179 0.3688 0.4498
AsPC-1 GDSC2 3.6798 5.5836 0.38 0.3858
Panc 10.05 GDSC2 3.725 5.7582 0.3345 0.4762
HPAF-II GDSC2 3.7598 5.683 0.3748 0.3675
KP-1N GDSC2 3.9222 6.0322 0.3117 0.449
HuP-T4 GDSC2 3.9809 6.0216 0.3377 0.3689
BxPC-3 GDSC2 4.061 5.884 0.4146 0.2055
KP-3 GDSC2 4.1251 6.4424 0.2421 0.5329
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MSTO-211H GDSC2 3.028 5.1071 0.2902 1.0531
MPP 89 GDSC2 3.1568 4.8578 0.4399 0.4649
NCI-H2052 GDSC2 3.2417 5.2259 0.3371 0.7271
IST-Mes1 GDSC2 3.5051 5.294 0.4171 0.3683
NCI-H28 GDSC2 3.9807 5.849 0.3979 0.2525
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PC-3 GDSC2 2.3696 5.2304 -0.112 3.9117
22Rv1 GDSC2 2.9719 4.9456 0.3287 0.9514
LNCaP clone FGC GDSC2 3.6544 5.683 0.3343 0.5085
DU145 GDSC2 3.7056 5.5005 0.419 0.2934
VCaP GDSC2 3.8506 5.3149 0.5334 0.0922
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 GDSC2 3.9084 5.536 0.4793 0.1451
Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A2058 GDSC2 1.7462 3.3856 0.3569 2.3453
HT-144 GDSC2 2.3867 6.0611 -0.4892 6.0583
SK-MEL-2 GDSC2 2.3874 3.3324 0.6934 0.1681
CP66-MEL GDSC2 2.4901 3.8268 0.5526 0.5056
RPMI-7951 GDSC2 2.5075 11.6996 -3.1513 19.5924
UACC-62 GDSC2 2.5275 3.6284 0.641 0.2329
G-mel GDSC2 2.5291 4.451 0.3207 1.4089
IGR-37 GDSC2 2.6599 3.8981 0.5948 0.2897
COLO 829 GDSC2 2.7179 4.5736 0.3611 1.0418
WM278 GDSC2 2.8996 4.8521 0.3331 0.9941
WT2-iPS GDSC2 2.9039 4.0316 0.638 0.1246
WM115 GDSC2 2.9695 4.5328 0.4848 0.4347
G-361 GDSC2 2.9884 4.581 0.4746 0.4537
A101D GDSC2 3.0011 4.4544 0.5257 0.3146
UACC-257 GDSC2 3.0127 4.5275 0.5038 0.3636
GAK GDSC2 3.0321 4.2178 0.6197 0.1239
SK-MEL-5 GDSC2 3.0669 4.2979 0.6047 0.1388
IGR-1 GDSC2 3.1206 4.6884 0.4873 0.3576
WM793 GDSC2 3.144 4.8804 0.4265 0.5093
COLO 679 GDSC2 3.191 5.2277 0.3149 0.8362
HMV-II GDSC2 3.2351 5.8402 0.0914 1.6811
A-375 GDSC2 3.2433 4.9462 0.4416 0.4189
COLO 792 GDSC2 3.359 5.4373 0.3061 0.7531
SH-4 GDSC2 3.449 5.2245 0.4206 0.3824
SK-MEL-24 GDSC2 3.5471 5.0282 0.5251 0.1528
WM35 GDSC2 3.5583 5.6132 0.3219 0.5898
CHL-1 GDSC2 3.5643 5.3122 0.4329 0.3117
M14 GDSC2 3.5932 5.1806 0.4893 0.1975
WM1552C GDSC2 3.6789 5.5063 0.4071 0.3267
Mel JuSo GDSC2 3.7221 5.4501 0.4426 0.2439
LOX-IMVI GDSC2 3.7645 5.5178 0.4345 0.2467
⏷ Show the Full List of 31 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC2 1.9012 8.909 -2.2308 16.9378
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RD GDSC2 1.8134 3.5999 0.2991 2.5554
Rh41 GDSC2 2.042 3.9919 0.2574 2.3982
G-401 GDSC2 2.2578 8.8064 -1.911 14.3961
EW-8 GDSC2 2.259 5.4894 -0.3022 5.2156
VA-ES-BJ GDSC2 2.3305 4.2321 0.3118 1.6909
KYM-1 GDSC2 2.6262 4.3243 0.4186 0.8924
RKN GDSC2 2.6964 4.1938 0.4999 0.5451
Rh30 GDSC2 2.7179 4.5582 0.3672 1.0169
SW684 GDSC2 2.7491 4.2234 0.5106 0.4794
GCT GDSC2 2.8962 4.8978 0.3134 1.0746
G-402 GDSC2 2.9127 6.0174 -0.1511 3.2548
SW982 GDSC2 2.9637 4.3006 0.5663 0.2375
SW872 GDSC2 3.0611 5.3272 0.2175 1.3155
MES-SA GDSC2 3.153 4.3591 0.6141 0.108
SK-LMS-1 GDSC2 3.1971 4.7325 0.5007 0.296
HT-1080 GDSC2 3.6453 5.0059 0.5665 0.0861
SK-UT-1 GDSC2 3.852 9.2777 -1.0729 6.6496
A-204 GDSC2 4.5055 7.5537 -0.016 1.0695
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 21 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
GCIY GDSC2 1.786 4.0818 0.0547 4.0485
AGS GDSC2 1.8722 6.4217 -1.0228 10.3732
HGC-27 GDSC2 2.1825 4.1055 0.2868 2.0226
23132/87 GDSC2 2.2471 4.3206 0.2277 2.2392
MKN45 GDSC2 2.3549 3.353 0.6738 0.2253
NCI-N87 GDSC2 2.6824 5.1594 0.0985 2.2941
Hs 746.T GDSC2 2.74 4.7406 0.3039 1.2606
MKN1 GDSC2 2.7507 4.6534 0.3442 1.0808
IM95 GDSC2 2.8111 5.4539 0.0398 2.4178
SNU-5 GDSC2 2.8754 4.4961 0.4603 0.5605
NUGC-4 GDSC2 3.0453 4.7018 0.4528 0.486
OCUM-1 GDSC2 3.0766 5.0874 0.3195 0.9037
KATO III GDSC2 3.1273 5.0299 0.3634 0.7147
NUGC-3 GDSC2 3.2698 4.894 0.4707 0.3364
RERF-GC-1B GDSC2 3.4666 7.182 -0.3581 3.5369
ECC10 GDSC2 3.5299 5.247 0.4431 0.3021
RF-48 GDSC2 3.5438 5.1826 0.4708 0.2431
SNU-1 GDSC2 3.5631 5.1437 0.4912 0.2018
SK-GT-2 GDSC2 4.0137 6.4357 0.2007 0.6961
MKN28 GDSC2 4.4023 6.4786 0.3322 0.2555
SNG-M GDSC2 3.4876 5.8945 0.1856 1.0797
⏷ Show the Full List of 21 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 12 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CAL-62 GDSC2 2.4774 4.2302 0.3868 1.167
8305C GDSC2 2.5789 5.3371 -0.037 3.1506
TT2609-C02 GDSC2 2.7434 4.5839 0.3687 0.9883
B-CPAP GDSC2 2.8028 4.3086 0.5007 0.4784
BHT-101 GDSC2 2.8949 4.4308 0.4926 0.4515
ASH-3 GDSC2 2.9178 4.3429 0.5338 0.3299
IHH-4 GDSC2 3.0062 4.4847 0.5167 0.3341
FTC-133 GDSC2 3.1165 4.5287 0.5427 0.2352
WRO GDSC2 3.3595 5.5082 0.2793 0.8417
K5 GDSC2 3.616 5.3647 0.4336 0.293
HTC-C3 GDSC2 3.6432 5.4035 0.43 0.2914
8505C GDSC2 4.2921 6.121 0.4151 0.1585
⏷ Show the Full List of 12 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
UPCI-SCC-090 GDSC2 1.8078 7.719 -1.7123 14.4752
SCC-15 GDSC2 2.329 4.7233 0.0946 2.8296
BICR 10 GDSC2 2.4478 7.8466 -1.3047 10.6459
SCC-4 GDSC2 2.7236 4.4212 0.424 0.7913
BICR 22 GDSC2 2.7419 4.2037 0.515 0.4699
HSC-4 GDSC2 2.8384 4.6761 0.3751 0.8836
BB49-HNC GDSC2 2.8465 5.5349 0.0236 2.4521
JHU-022 GDSC2 3.0106 6.3591 -0.2475 3.6171
HSC-2 GDSC2 3.0118 4.3061 0.5821 0.1912
CAL-27 GDSC2 3.0123 12.3757 -3.1104 18.2272
FaDu GDSC2 3.0719 4.7364 0.4507 0.4781
CAL-33 GDSC2 3.1623 5.0014 0.3888 0.6114
HSC-3 GDSC2 3.1844 4.6412 0.5282 0.2423
SKN-3 GDSC2 3.269 5.2049 0.3564 0.6487
OSC-20 GDSC2 3.3958 5.3078 0.3695 0.5395
Detroit 562 GDSC2 3.4223 5.2705 0.3937 0.4611
BICR 78 GDSC2 3.4892 5.3898 0.3765 0.4751
SAS GDSC2 3.5984 5.6376 0.3289 0.5499
HO-1-N-1 GDSC2 3.6039 5.277 0.4598 0.2461
PCI-04B GDSC2 3.6064 5.8355 0.2587 0.7514
SCC-9 GDSC2 3.6295 5.3187 0.4546 0.2483
SAT [Human HNSCC] GDSC2 3.6737 6.3368 0.0949 1.2705
LB771-HNC GDSC2 4.0086 5.8397 0.4112 0.2231
Ca9-22 GDSC2 4.0888 5.966 0.3964 0.2276
NCI-H3118 GDSC2 4.1523 6.3673 0.2794 0.4341
DOK GDSC2 4.2668 6.4533 0.2917 0.3679
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 13 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
J82 GDSC2 1.5777 7.467 -1.7655 15.3792
KU-19-19 GDSC2 2.3782 3.7283 0.5423 0.622
SW780 GDSC2 2.6641 5.4276 -0.029 2.979
TCCSUP GDSC2 2.6744 4.8879 0.2104 1.7562
639V GDSC2 2.7848 4.161 0.548 0.3535
RT-112 GDSC2 2.8173 4.8661 0.2896 1.2457
HT-1197 GDSC2 2.8558 4.1191 0.5902 0.2243
BFTC-905 GDSC2 3.0924 4.3364 0.6006 0.1393
647V GDSC2 3.1687 4.5854 0.542 0.2202
CAL-29 GDSC2 3.1777 4.6034 0.539 0.2232
SW1710 GDSC2 3.2169 5.0864 0.3794 0.6085
5637 GDSC2 3.6156 5.7649 0.2888 0.6547
RT-4 GDSC2 3.8391 6.1467 0.2374 0.6833
⏷ Show the Full List of 13 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DSH1 GDSC2 1.6884 4.2205 -0.0789 5.069
NEC8 GDSC2 1.8837 4.0512 0.133 3.3889
PA-1 GDSC2 2.1273 7.1552 -1.1961 10.7707
SiHa GDSC2 2.6092 3.9484 0.5562 0.4215
HeLa GDSC2 2.7563 4.3231 0.476 0.5851
SiSo GDSC2 2.8544 4.9508 0.2727 1.2814
SW756 GDSC2 2.925 4.463 0.4928 0.4352
C-4-I GDSC2 3.0898 4.6841 0.477 0.3976
TC-YIK GDSC2 3.177 5.0468 0.3778 0.637
OVMIU GDSC2 3.215 5.9318 0.0439 1.9129
MS751 GDSC2 3.2677 5.0447 0.4153 0.4772
HEC-1 GDSC2 3.2823 4.8682 0.4846 0.3004
CAL-39 GDSC2 3.3657 5.6274 0.2361 0.9884
C-33 A GDSC2 3.3666 5.3427 0.3448 0.6273
PWR-1E GDSC2 3.4091 5.2754 0.3867 0.4859
ME-180 GDSC2 3.4305 5.6152 0.2686 0.8303
SKG-IIIa GDSC2 3.5724 5.2186 0.4687 0.2388
LB831-BLC GDSC2 3.5854 5.6976 0.3016 0.6339
Ca Ski GDSC2 3.5993 6.3098 0.0721 1.42
DoTc2 4510 GDSC2 3.6063 5.3071 0.4502 0.2634
OVCA420 GDSC2 3.6429 5.4505 0.4134 0.3258
HT-3 GDSC2 3.7009 5.9893 0.2399 0.7536
PEO1 GDSC2 3.9797 5.8379 0.4014 0.2468
BPH-1 GDSC2 4.0291 6.3931 0.2225 0.6279
SKN GDSC2 4.1169 6.1079 0.3575 0.2871
HEY GDSC2 4.1478 6.5453 0.2136 0.5951
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Zoledronate
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Gallium nitrate DMF9O6B Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Gallium nitrate. Mineral excesses [5B91] [17]
Coadministration of a Drug Treating the Disease Different from Zoledronate (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Decreased renal excretion of Zoledronate caused by Remdesivir mediated nephrotoxicity. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [18]
Framycetin DMF8DNE Moderate Increased risk of hypocalcemia by the combination of Zoledronate and Framycetin. Alcoholic liver disease [DB94] [17]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Zoledronate and Inotersen. Amyloidosis [5D00] [19]
Kanamycin DM2DMPO Moderate Increased risk of hypocalcemia by the combination of Zoledronate and Kanamycin. Bacterial infection [1A00-1C4Z] [17]
Amikacin DM5PDRB Moderate Increased risk of hypocalcemia by the combination of Zoledronate and Amikacin. Bacterial infection [1A00-1C4Z] [17]
Streptomycin DME1LQN Moderate Increased risk of hypocalcemia by the combination of Zoledronate and Streptomycin. Bacterial infection [1A00-1C4Z] [17]
Gentamicin DMKINJO Moderate Increased risk of hypocalcemia by the combination of Zoledronate and Gentamicin. Bacterial infection [1A00-1C4Z] [17]
Netilmicin DMRD1QK Moderate Increased risk of hypocalcemia by the combination of Zoledronate and Netilmicin. Bacterial infection [1A00-1C4Z] [17]
Tobramycin DMUI0CH Moderate Increased risk of hypocalcemia by the combination of Zoledronate and Tobramycin. Bacterial infection [1A00-1C4Z] [17]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Zoledronate and Iodipamide. Cholelithiasis [DC11] [20]
Ketoprofen DMRKXPT Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Ketoprofen. Chronic pain [MG30] [19]
Oxaliplatin DMQNWRD Moderate Decreased renal excretion of Zoledronate caused by Oxaliplatin mediated nephrotoxicity. Colorectal cancer [2B91] [21]
Methoxyflurane DML0RAE Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Methoxyflurane. Corneal disease [9A76-9A78] [17]
Ethacrynic acid DM60QMR Moderate Increased risk of hypocalcemia by the combination of Zoledronate and Ethacrynic acid. Essential hypertension [BA00] [22]
Mefenamic acid DMK7HFI Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Zoledronate and Mefenamic acid. Female pelvic pain [GA34] [19]
Amphotericin B DMTAJQE Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Amphotericin B. Fungal infection [1F29-1F2F] [17]
Furosemide DMMQ8ZG Moderate Increased risk of hypocalcemia by the combination of Zoledronate and Furosemide. Heart failure [BD10-BD1Z] [23]
Bumetanide DMRV7H0 Moderate Increased risk of hypocalcemia by the combination of Zoledronate and Bumetanide. Heart failure [BD10-BD1Z] [23]
177Lu-DOTATATE DMT8GVU Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [17]
Etelcalcetide DMHP9BL Major Increased risk of hypocalcemia by the combination of Zoledronate and Etelcalcetide. Hyper-parathyroidism [5A51] [19]
Givosiran DM5PFIJ Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [17]
Balsalazide DM7I1T9 Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Balsalazide. Indeterminate colitis [DD72] [17]
Meclofenamic acid DM05FXR Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Zoledronate and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [24]
Methotrexate DM2TEOL Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Methotrexate. Leukaemia [2A60-2B33] [17]
Moxetumomab pasudotox DMN63DZ Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Moxetumomab pasudotox. Mature B-cell leukaemia [2A82] [17]
Clofarabine DMCVJ86 Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Clofarabine. Mature B-cell lymphoma [2A85] [25]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Zoledronate and Exjade. Mineral absorption/transport disorder [5C64] [26]
Thalidomide DM70BU5 Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Thalidomide. Multiple myeloma [2A83] [23]
Rofecoxib DM3P5DA Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Rofecoxib. Osteoarthritis [FA00-FA05] [19]
Valdecoxib DMAY7H4 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Zoledronate and Valdecoxib. Osteoarthritis [FA00-FA05] [19]
Diclofenac DMPIHLS Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Zoledronate and Diclofenac. Osteoarthritis [FA00-FA05] [19]
Aspirin DM672AH Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Zoledronate and Aspirin. Pain [MG30-MG3Z] [24]
Etodolac DM6WJO9 Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Etodolac. Pain [MG30-MG3Z] [19]
Diflunisal DM7EN8I Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Diflunisal. Pain [MG30-MG3Z] [19]
Ibuprofen DM8VCBE Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Zoledronate and Ibuprofen. Pain [MG30-MG3Z] [19]
Nabumetone DMAT2XH Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Zoledronate and Nabumetone. Pain [MG30-MG3Z] [19]
Piroxicam DMTK234 Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Piroxicam. Pain [MG30-MG3Z] [19]
Choline salicylate DM8P137 Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Choline salicylate. Postoperative inflammation [1A00-CA43] [19]
Ketorolac DMI4EL5 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Zoledronate and Ketorolac. Postoperative inflammation [1A00-CA43] [19]
Bromfenac DMKB79O Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Zoledronate and Bromfenac. Postoperative inflammation [1A00-CA43] [19]
Temsirolimus DMS104F Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Temsirolimus. Renal cell carcinoma [2C90] [17]
Colistimethate DMZ9BMU Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Colistimethate. Respiratory infection [CA07-CA4Z] [17]
Salsalate DM13P4C Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Zoledronate and Salsalate. Rheumatoid arthritis [FA20] [19]
Meloxicam DM2AR7L Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Meloxicam. Rheumatoid arthritis [FA20] [19]
Sulindac DM2QHZU Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Sulindac. Rheumatoid arthritis [FA20] [19]
Celecoxib DM6LOQU Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Zoledronate and Celecoxib. Rheumatoid arthritis [FA20] [19]
Oxaprozin DM9UB0P Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Zoledronate and Oxaprozin. Rheumatoid arthritis [FA20] [19]
Flurbiprofen DMGN4BY Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Flurbiprofen. Rheumatoid arthritis [FA20] [19]
Fenoprofen DML5VQ0 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Zoledronate and Fenoprofen. Rheumatoid arthritis [FA20] [19]
Tolmetin DMWUIJE Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Tolmetin. Rheumatoid arthritis [FA20] [19]
Salicyclic acid DM2F8XZ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Zoledronate and Salicyclic acid. Seborrhoeic dermatitis [EA81] [24]
Bacitracin DM5OHYE Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Bacitracin. Skin and skin-structure infection [1F28-1G0Z] [17]
Cisplatin DMRHGI9 Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Cisplatin. Solid tumour/cancer [2A00-2F9Z] [17]
Telavancin DM58VQX Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [17]
Lenvatinib DMB1IU4 Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Lenvatinib. Thyroid cancer [2D10] [17]
Sirolimus DMGW1ID Major Increased risk of nephrotoxicity by the combination of Zoledronate and Sirolimus. Transplant rejection [NE84] [27]
Tacrolimus DMZ7XNQ Major Increased risk of nephrotoxicity by the combination of Zoledronate and Tacrolimus. Transplant rejection [NE84] [27]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Zoledronate and Olsalazine. Ulcerative colitis [DD71] [17]
Plazomicin DMKMBES Moderate Increased risk of hypocalcemia by the combination of Zoledronate and Plazomicin. Urinary tract infection [GC08] [17]
⏷ Show the Full List of 59 DDI Information of This Drug

References

1 In vitro cytotoxicity of zoledronate (nitrogen-containing bisphosphonate: NBP) and/or etidronate (non-NBP) in tumour cells and periodontal cells. Arch Oral Biol. 2013 Jun;58(6):628-37.
2 Giant Cell Tumor of Bone: Review of Current Literature, Evaluation, and Treatment Options. J Knee Surg. 2019 Apr;32(4):331-336.
3 Paget's Disease of Bone: Diagnosis and Treatment. Am J Med. 2018 Nov;131(11):1298-1303.
4 Current and future treatments of bone metastases. Expert Opin Emerg Drugs. 2008 Dec;13(4):609-27.
5 Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008 Apr 15;14(8):2387-95.
6 AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. Endocr Pract. 2020 May;26(Suppl 1):1-46.
7 Shiraki M, Tanaka S, Suzuki H, Ueda S, Nakamura T: Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis. J Bone Miner Metab. 2017 Nov;35(6):675-684. doi: 10.1007/s00774-016-0806-3. Epub 2016 Dec 20.
8 BDDCS applied to over 900 drugs
9 FDA Approved Drug Products: Zometa Zoledronic Acid Intravenous Injection
10 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
11 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
13 Zoledronic acid is synergic with vinblastine to induce apoptosis in a multidrug resistance protein-1 dependent way: an in vitro study. Cell Biol Int. 2006 Mar;30(3):278-82.
14 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
15 The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
16 Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity. Arch Toxicol. 2018 Jan;92(1):469-485.
17 Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D "Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity." Am J Kidney Dis 41 (2003): E18. [PMID: 12778436]
18 Cerner Multum, Inc. "Australian Product Information.".
19 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
20 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
21 Product Information. Eloxatin (oxaliplatin). Sanofi Winthrop Pharmaceuticals, New York, NY.
22 Product Information. Skelid (tilundronate). Sanofi Winthrop Pharmaceuticals, New York, NY.
23 Product Information. Zometa (zoledronic acid). Novartis Pharmaceuticals, East Hanover, NJ.
24 Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
25 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
26 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
27 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.